PER Contextualizing Advances in Relapse Refractory DLBCL: Navigating Biomarkers, Emerging Data, and Adverse Event Management to Transform Patient Care

Details

Management approaches for DLBCL have grown more complex over the past decade, as novel therapies have been incorporated into the treatment algorithm. Knowledge of which patients should receive which therapy is imperative for ensuring an optimal patient journey. In this program, expert faculty in the management of DLBCL discuss principles for treatment selection and management of adverse events associated with novel therapies for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)

Topics Covered

Hematology

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Identify current and emerging biomarkers that can inform clinical decision-making in patients with DLBCL.
• Describe how results of biomarker testing can be used to determine targeted treatments for patients with DLBCL
• Assess recent pivotal trial data investigating targeted agents in patients with DLBCL across multiple lines of care
• Select appropriate treatment strategies for patients with relapsed/refractory DLBCL, considering efficacy, safety, and patient-specific factors, to optimize patient outcomes
• Discuss mechanisms of treatment resistance/lack of response in patients with DLBCL and how they can affect treatment sequencing in DLBCL
• Recognize adverse events associated with the different classes of targeted therapies used in R/R DLBCL treatment sequencing in DLBCL
• Formulate strategies for the monitoring, identification, and mitigation of toxicities linked to targeted agents in patients with DLBCL

Target Audience

This online educational activity is primarily directed toward academic and community hematologists, oncologists, oncology nurses, oncology advanced practice providers, oncology pharmacists, and other health care providers involved in the diagnosis and management of patients with DLBCL.

Additional credit info

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2 Contact Hours.